Jun 2026 (Q2 FY26) — Aug 4, 2026
Pediatrix Medical Group Q2 FY26 — Solid Adjusted EBITDA and Share Buybacks
Read the full callPediatrix Medical Group (MD) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Pediatrix Medical Group earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 488 | +4.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 11.7 | −1.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 39.8 | +1.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$27.3 −0.29% · −$0.08
Performance +66.0% 1Y
1Y: $16.45 on 17 Oct 2025 → $27.3. High $27.76 (15 Oct 2026), low $16.45 (17 Oct 2025).
- Previous close
- $27.38
- 52-week range
- $16.88 – $27.76
- One year
- +61.73%
Overview
- Symbol
- MD
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Pediatrix Medical Group earnings calls (MD)
Financials
What the filings say
Net profit, year on year: +1% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 511 | 502 | 458 | 469 | 493 | 494 | 476 | 488 |
| Operating profit | 34 | 39 | 32 | 60 | 68 | 49 | 42 | 57 |
| Operating margin | 6.6% | 7.8% | 7.0% | 12.8% | 13.8% | 9.9% | 8.8% | 11.7% |
| Other income | -9 | -6 | -4 | -5 | 20 | -3 | -3 | -3 |
| Interest | 10 | 10 | 9 | 9 | 9 | 9 | 8 | 8 |
| Profit before tax | 25 | 33 | 28 | 55 | 88 | 46 | 39 | 54 |
| Tax rate | 23.0% | 8.6% | 26.2% | 28.6% | 18.3% | 26.1% | 23.9% | 26.2% |
| Net profit | 19 | 30 | 21 | 39 | 72 | 34 | 30 | 40 |
| EPS ($ per share) | 0.23 | — | 0.25 | 0.46 | 0.85 | — | 0.37 | 0.50 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves | 2,094 | 510 | -286 | -155 | -89 | -149 | -249 | -83 |
| Total liabilities | 2,850 | 2,647 | 2,600 | 1,826 | 1,456 | 1,371 | 1,388 | 1,381 |
| Fixed assets | 90 | 73 | 76 | 70 | 73 | 76 | 39 | 39 |
| Investments | 22 | 0 | — | — | — | — | — | — |
| Total assets | 5,937 | 4,146 | 3,348 | 2,723 | 2,348 | 2,220 | 2,153 | 2,247 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 314 | 358 | 205 | 77 | 167 | 137 | 207 | 271 |
| Cash from investing | -143 | 102 | 816 | -53 | -57 | -48 | -35 | -18 |
| Cash from financing | -171 | -393 | -4 | -760 | -488 | -26 | -14 | -107 |
| Net cash flow | 0 | 67 | 1,016 | -736 | -378 | 63 | 157 | 145 |
| Capital expenditure | -17 | -19 | -29 | -32 | -30 | -33 | -22 | -18 |
| Free cash flow | 297 | 338 | 176 | 44 | 137 | 104 | 185 | 253 |
Insider filings
40 filings between Nov 6, 2025 and Sep 10, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$1.83M
4 sales by 4 insiders
Compensation
not trading decisions- 22
- Award — granted as compensation
- 6
- Tax withheld — shares kept back by the company to cover tax
Also filed: 5 gifts, 3 dispositions to the issuer.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Weis Shirley A | — | $855.7K | May 13, 2026 |
| ORDAN MARK S | — | $515.4K | Dec 15, 2025 |
| Rucker Michael A. | — | $241.0K | Nov 17, 2025 |
| Linynsky Laura A | — | $216.5K | Nov 6, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2026 | Linynsky Laura A Director | Disposition to issuer | 6,000 | $160.9K |
| Aug 14, 2026 | Young Sylvia Jean Director | Disposition to issuer | 18,500 | $492.5K |
| Aug 12, 2026 | Rucker Michael A. Director | Award | 472 | $12.5K |
| Aug 12, 2026 | Linynsky Laura A Director | Award | 472 | $12.5K |
| Aug 12, 2026 | Newman Kurt Douglas Director | Award | 472 | $12.5K |
| Aug 12, 2026 | Starcher John M. Jr. Director | Award | 472 | $12.5K |
| Aug 12, 2026 | Weis Shirley A Director | Award | 472 | $12.5K |
| Aug 12, 2026 | McEachin Thomas Director | Award | 472 | $12.5K |
| Aug 12, 2026 | SANSONE GUY P Director | Award | 472 | $12.5K |
| Aug 12, 2026 | Young Sylvia Jean Director | Award | 472 | $12.5K |
| Jun 22, 2026 | Haddock David EVP, GC & Corp Sec | Award | 20,036 | $0 |
| Jun 9, 2026 | Moore Mary Ann E EVP, GC, Chief Admin Off & Sec | Gift | 18,407 | $0 |
| Jun 9, 2026 | Moore Mary Ann E EVP, GC, Chief Admin Off & Sec | Gift | 18,407 | $0 |
| Jun 2, 2026 | ORDAN MARK S Chief Executive Officer | Disposition to issuer | 97,174 | $0 |
| Jun 2, 2026 | ORDAN MARK S Chief Executive Officer | Award | 97,174 | $0 |
| Jun 1, 2026 | ORDAN MARK S Chief Executive Officer | Award | 127,198 | $0 |
| Jun 1, 2026 | ORDAN MARK S Chief Executive Officer | Tax withheld | 19,119 | $411.8K |
| Jun 1, 2026 | Rossi Kasandra H EVP, CFO and Treasurer | Award | 31,800 | $0 |
| Jun 1, 2026 | Rossi Kasandra H EVP, CFO and Treasurer | Tax withheld | 3,701 | $79.7K |
| Jun 1, 2026 | Neeb Don Gregory EVP, Chief Invest & Strategy | Award | 63,888 | $0 |
| Jun 1, 2026 | Neeb Don Gregory EVP, Chief Invest & Strategy | Tax withheld | 8,003 | $172.4K |
| Jun 1, 2026 | Moore Mary Ann E EVP, GC, Chief Admin Off & Sec | Tax withheld | 11,944 | $257.3K |
| May 13, 2026 | McEachin Thomas Director | Gift | 11,427 | $0 |
| May 13, 2026 | Weis Shirley A Director | Sale | 36,028 | $855.7K |
| May 13, 2026 | McEachin Thomas Director | Gift | 11,427 | $0 |
| May 11, 2026 | Moore Mary Ann E EVP, GC, Chief Admin Off & Sec | Gift | 40,826 | $0 |
| May 7, 2026 | McEachin Thomas Director | Award | 7,196 | $0 |
| May 7, 2026 | Weis Shirley A Director | Award | 7,196 | $0 |
| May 7, 2026 | Starcher John M. Jr. Director | Award | 7,196 | $0 |
| May 7, 2026 | Newman Kurt Douglas Director | Award | 7,196 | $0 |
| May 7, 2026 | SANSONE GUY P Director | Award | 7,196 | $0 |
| May 7, 2026 | Linynsky Laura A Director | Award | 7,196 | $0 |
| May 7, 2026 | Rucker Michael A. Director | Award | 7,196 | $0 |
| May 7, 2026 | Young Sylvia Jean Director | Award | 7,196 | $0 |
| Mar 1, 2026 | Rossi Kasandra H EVP, CFO and Treasurer | Tax withheld | 3,676 | $73.0K |
| Mar 1, 2026 | Moore Mary Ann E EVP, GC, Chief Admin Off & Sec | Award | 39,925 | $0 |
| Mar 1, 2026 | Moore Mary Ann E EVP, GC, Chief Admin Off & Sec | Tax withheld | 26,931 | $534.6K |
| Dec 15, 2025 | ORDAN MARK S Chief Executive Officer | Sale | 23,000 | $515.4K |
| Nov 17, 2025 | Rucker Michael A. Director | Sale | 10,478 | $241.0K |
| Nov 6, 2025 | Linynsky Laura A Director | Sale | 10,000 | $216.5K |
| Aug 20, 2025 | McEachin Thomas Director | Gift | 625 | $0 |
| Aug 19, 2025 | McEachin Thomas Director | Gift | 54,021 | $0 |
| Aug 1, 2025 | Neeb Don Gregory EVP, Chief Invest & Strategy | Award | 81,346 | $0 |
| Aug 1, 2025 | Newman Kurt Douglas Director | Award | 9,737 | $0 |
| Jun 10, 2025 | Moore Mary Ann E EVP, GC, Chief Admin Off & Sec | Gift | 10,371 | $0 |
| Jun 1, 2025 | Moore Mary Ann E EVP, GC, Chief Admin Off & Sec | Tax withheld | 6,729 | $95.2K |
| Jun 1, 2025 | ORDAN MARK S Chief Executive Officer | Award | 194,347 | $0 |
| Jun 1, 2025 | Rossi Kasandra H EVP, CFO and Treasurer | Award | 26,502 | $0 |
| Jun 1, 2025 | Rossi Kasandra H EVP, CFO and Treasurer | Tax withheld | 677 | $9.6K |
| Jun 1, 2025 | Moore Mary Ann E EVP, GC, Chief Admin Off & Sec | Award | 53,004 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Pediatrix Medical Group, Inc.
Free account. Everything above stays public.
Write why you follow Pediatrix Medical Group, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading